SIGHT SCIENCES INC. - COMMON STOCK

Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022

20 Oct 2022 17:20:54 By Nasdaq GlobeNewswire

Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)

29 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

28 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting

16 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare® System vs Restasis®

13 Sep 2022 03:01:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

02 Sep 2022 08:00:00 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

25 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

23 Aug 2022 08:03:39 By Nasdaq GlobeNewswire

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

16 Aug 2022 08:01:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Second Quarter 2022 Financial Results

11 Aug 2022 16:05:02 By Nasdaq GlobeNewswire

Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022

28 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Sight Sciences Announces the Appointment of Tamara Fountain, M.D. to its Board of Directors

19 Jul 2022 16:26:27 By Nasdaq GlobeNewswire

Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data

31 May 2022 08:00:01 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Piper Sandler Virtual Ophthalmology & Diabetes Symposium

19 May 2022 08:00:00 By Nasdaq GlobeNewswire

Sight Sciences Reports First Quarter 2022 Financial Results

10 May 2022 16:05:02 By Nasdaq GlobeNewswire

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

29 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Sight Sciences Announces Multiple Presentations and Event at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

20 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences to Report First Quarter 2022 Financial Results on May 10, 2022

14 Apr 2022 16:05:00 By Nasdaq GlobeNewswire

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Results

24 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

24 Mar 2022 16:04:00 By Nasdaq GlobeNewswire